Page 70 - Read Online

Page 12 of 12 Ma et al. Hepatoma Res 2019;5:8 I http://dx.doi.org/10.20517/2394-5079.2018.104

71. Lau CC, Sun T, Ching AK, He M, Li JW, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and
progression. Cancer Cell 2014;25:335-49.
72. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV
infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.
73. Yan H, Yang Y, Zhang L, Tang G, Wang Y, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early-
and late-onset hepatocellular carcinoma. Hepatology 2015;61:1821-31.
74. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic
chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256-64.
75. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.
Nat Commun 2016;7:12992.
76. Lee WY, Bachtiar M, Choo CCS, Lee CG. Comprehensive review of hepatitis B virus-associated hepatocellular carcinoma research
through text mining and big data analytics. Biol Rev Camb Philos Soc 2018; doi: 10.1111/brv.12457.
77. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, et al. Exome sequencing of hepatocellular carcinomas identifies new
mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
78. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas.
Int J Oncol 2009;34:391-9.
79. Kumakura S, Tsutsui TW, Yagisawa J, Barrett JC, Tsutsui T. Reversible conversion of immortal human cells from telomerase-positive
to telomerase-negative cells. Cancer Res 2005;65:2778-86.
80. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, et al. Methylation status and expression of human telomerase
reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004;93:407-16.
81. Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression
and telomerase activity and shortened telomeres. Exp Cell Res 2003;289:326-34.
82. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, et al. Hypermethylation of the human telomerase catalytic subunit (hTERT)
gene correlates with telomerase activity. Int J Cancer 2002;101:335-41.
83. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res
2000;60:537-41.
84. Zhang H, Weng X, Ye J, He L, Zhou D, et al. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the
Han Chinese population. Clin Res Hepatol Gastroenterol 2015;39:600-9.
85. Li Y, Zhou QL, Sun W, Chandrasekharan P, Cheng HS, et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive
C250T mutant TERT promoter activation. Nat Cell Biol 2015;17:1327-38.
86. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, et al. Cancer. The transcription factor GABP selectively binds and activates the
mutant TERT promoter in cancer. Science 2015;348:1036-9.
87. Liu X, Bishop J, Shan Y, Pai S, Liu D, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer 2013;20:603-10.
88. Xing M, Liu R, Liu X, Murugan AK, Zhu G, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most
aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32:2718-26.
89. Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, et al. Coexistence of TERT promoter and BRAF mutations in
cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 2015;467:177-84.
90. Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter
mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol
2016; doi: 10.1001/jamaoncol.2016.3288.
91. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016;23:R143-55.
92. Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, et al. TERT promoter mutations in melanoma survival. Int J
Cancer 2016;139:75-84.
93. Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human
cancer. Nat Commun 2018;9:579.
94. Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-
activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014;25:428-41.
95. Ko E, Seo HW, Jung ES, Kim BH, Jung G. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and
increases mortality and recurrence risks in liver cancer. Oncotarget 2016;7:684-99.
96. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of
telomerase activity via NF-kappaB-dependent transcription. FASEB J 2013;27:4375-83.
97. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. Telomerase modulates Wnt signalling by association with target gene chromatin.
Nature 2009;460:66-72.
98. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. Both Rb/p16INK4a inactivation and telomerase activity are
required to immortalize human epithelial cells. Nature 1998;396:84-8.
99. Li X, Xu W, Kang W, Wong SH, Wang M, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic
features. Theranostics 2018;8:1740-51.
100. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention
and therapy. Gastroenterology 2019;156:492-509.
101. Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, et al. Immunological features of T cells induced by human telomerase
reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Lett 2015;364:98-105.
102. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, et al. Comparative analysis of various tumor-associated antigen-specific
t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-16.